Home » Newsletters » BioWorld Science

BioWorld Science

July 24, 2020

View Archived Issues

Janpix describes small-molecule monovalent STAT3 and STAT5 protein degraders

CStone Pharmaceuticals presents data on the CDK4/6 inhibitor CS-3002

Phase II/III study begins with mavrilimumab in severe COVID-19 pneumonia and hyperinflammation

Bayer initiates first-in-human study of BAY-2701439 in advanced HER2-expressing cancers

M-6223 studied in first-in-human trial for metastatic or locally advanced solid unresectable tumors

Akeso begins phase II study of AK-104 in recurrent or metastatic cervical cancer

Fe-isty cancer cells flourish in hostile subarachnoid space

DS-6157a demonstrates promising efficacy in preclinical models of GIST

Novartis reports first-in-human data for BLZ-945

Regeneron reports preclinical data on 89Zr-labeled REGN-5054 antibody for CD8+ T-cell monitoring

Array BioPharma identifies new protein kinase inhibitors

Patient enrollment begins in Ampion COVID-19 program

In vivo studies show potent reversal of anticoagulation with VMX-COO1

Topline phase III data for favipiravir in patients with COVID-19

Promising preclinical data for NurOwn-derived exosome-based therapy for COVID-19 ARDS

Kaleido Biosciences initiates second study of KB-109 in outpatients with COVID-19

FDA lifts clinical hold on all development of seladelpar

Cybrexa Therapeutics details development of peptide-drug conjugate CBX-13 for solid tumors

Sareum reports findings with TYK2/JAK1 inhibitors in disease model of lupus

Exonbio launches SARS-CoV-2 monoclonal antibodies for research

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for Feb. 3, 2025.
Today's news in brief
Briefs
BioWorld MedTech briefs for Jan. 30, 2026.
Centessa’s CNT-9982 shows promise for MDD
BioWorld Science
Orexin OX2 receptor agonists have demonstrated the ability to enhance wakefulness in rodent models, as well as in nonhuman primates and patients with narcolepsy...
First-in-class ADC targeting DEM-TXX shows high preclinical efficacy
BioWorld Science
Researchers at DEM Biopharma Inc. reported preclinical findings demonstrating the efficacy of DEM-301, a bifunctional antibody-drug conjugate (ADC) engineered to...
5-HT2R allosteric ligands attenuate cocaine use and seeking behavior
BioWorld Science
Serotonergic G-protein-coupled receptors (GPCRs), including the 5-HT2A receptor (5-HT2AR) and 5-HT2CR, are key regulators of cortical signaling pathways and...